vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vedolizumab

Bioactivity Comments
In vitro, vedolizumab inhibits specific binding of α4β7 +ve lymphoma cells to immobilised MADCAM1 or fibronectin with IC50 values of 0.39nM and 0.14nM respectively [2]. Soler et al. (2009) also show by FACS analysis that vedolizumab binds specifically to cells exogenously expressing the α4 and β7 intergrin proteins [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin α4β7 Primary target of this compound Hs Antibody Antagonist 8.3 pIC50 - 1
⤷ pIC50 8.3 (IC50 5.34x10-9 M) [1]
Description: Binding to HuT-78 cells
Ligand mentioned in the following text fields
Integrins overview